title: Preventing graft thrombosis after renal transplantation: a multicenter survey of clinical practice.
abstract: BACKGROUND
  Renal allograft vascular thrombosis is a complication that often results in graft loss. Since there are no guidelines on immediate postoperative thromboprophylaxis, we performed a telephone survey of clinical practice in all renal transplantation centers in France.
  
  
  METHODS
  Each center considered 4 cases relating to renal transplant candidates on dialysis with an increasing risk of thrombosis: Case 1: patient with no identified risk factors; Case 2: patient with an earlier incidence of deep vein thrombosis; Case 3: patient with ischemic heart disease on antiplatelet therapy; Case 4: patient with atrial fibrillation taking a vitamin K antagonist (VKA) with lupus nephritis syndrome.
  
  
  RESULTS
  The treatments proposed by the centers (%) were: Case 1: No anticoagulation therapy (57.1%), calcium heparin at prophylactic doses (P-dose) (40%), or unfractionated heparin (UFH); (P-dose; 2.9%). Case 2: No anticoagulation therapy (34.3%), calcium heparin (P-dose; 51.4%), or UFH (P-dose; 5.7%). Case 3: (A) Interruption of aspirin (65.7%), and either no anticoagulation therapy (21.7%) or substitution of aspirin by calcium heparin (P-dose; 56.6%) or by UFH (P-dose; 8.7%). (B) No interruption of aspirin (34.3%), and either no additional prophylaxis (58.3%) or calcium heparin (P-dose; 33.3%). Case 4: Interruption of VKA (100%), and UFH at a curative dose (68.6%), UFH (P-dose; 14.3%), or calcium heparin (P-dose; 11.4%).
  
  
  CONCLUSIONS
  Practices varied widely in the absence of studies of sufficiently high power. There is a need for a preoperative classification of thrombotic and hemorrhagic risk among renal transplant candidates and for consensus guidelines.
authors.affiliation: Department of Urology, CHU Robert Debre, REIMS, Champagne Ardennes, France. thomas_ripert@yahoo.fr
authors.forename: T
authors.initials: T
authors.lastname: Ripert
authors.forename: J
authors.initials: J
authors.lastname: Menard
authors.forename: Y
authors.initials: Y
authors.lastname: Schoepen
authors.forename: P
authors.initials: P
authors.lastname: Nguyen
authors.forename: P
authors.initials: P
authors.lastname: Rieu
authors.forename: F
authors.initials: F
authors.lastname: Staerman
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D005602:France; D006306:Health Surveys; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D048228:Intermittent Pneumatic Compression Devices; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010820:Physicians; D013689:Telephone; D017211:Treatment Failure; D020246:Venous Thrombosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; C006871:calcium heparin; D006493:Heparin; D001241:Aspirin